RT Journal Article
SR Electronic
T1 Who should we test for COVID-19? A triage model built from national symptom surveys
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.18.20105569
DO 10.1101/2020.05.18.20105569
A1 Shoer, Saar
A1 Karady, Tal
A1 Keshet, Ayya
A1 Shilo, Smadar
A1 Rossman, Hagai
A1 Gavrieli, Amir
A1 Meir, Tomer
A1 Lavon, Amit
A1 Kolobkov, Dmitry
A1 Kalka, Iris
A1 Godneva, Anastasia
A1 Cohen, Ori
A1 Kariv, Adam
A1 Hoch, Ori
A1 Zer-Aviv, Mushon
A1 Castel, Noam
A1 Sudre, Caroel
A1 Zohar, Anat Ekka
A1 Irony, Angela
A1 Spector, Tim
A1 Geiger, Benjamin
A1 Hizi, Dorit
A1 Shalev, Varda
A1 Balicer, Ran
A1 Segal, Eran
YR 2020
UL http://medrxiv.org/content/early/2020/06/08/2020.05.18.20105569.abstract
AB The gold standard for COVID-19 diagnosis is detection of viral RNA in a reverse transcription PCR test. Due to global limitations in testing capacity, effective prioritization of individuals for testing is essential. Here, we devised a model that estimates the probability of an individual to test positive for COVID-19 based on answers to 9 simple questions regarding age, gender, presence of prior medical conditions, general feeling, and the symptoms fever, cough, shortness of breath, sore throat and loss of taste or smell, all of which have been associated with COVID-19 infection. Our model was devised from a subsample of a national symptom survey that was answered over 2 million times in Israel over the past 2 months and a targeted survey distributed to all residents of several cities in Israel. Overall, 43,752 adults were included, from which 498 self-reported as being COVID-19 positive. We successfully validated the model on held-out individuals from Israel where it achieved a positive predictive value (PPV) of 46.3% at a 10% sensitivity and demonstrated its applicability outside of Israel by further validating it on an independently collected symptom survey dataset from the U.K., U.S. and Sweden, where it achieved a PPV of 34.7% at 10% sensitivity. Moreover, evaluating the model’s performance on this latter independent dataset on entries collected one week prior to the PCR test and up to the day of the test we found the highest performance on the day of the test. As our tool can be used online and without the need of exposure to suspected patients, it may have worldwide utility in combating COVID-19 by better directing the limited testing resources through prioritization of individuals for testing, thereby increasing the rate at which positive individuals can be identified and isolated.Competing Interest StatementThe authors have declared no competing interest.Funding Statementno external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Weizmann Institute of Science review board (IRB). Informed consent was waived by the IRB, as all identifying details of the participants were removed before the computational analysis. Participants were made fully aware of the way in which the data will be stored, handled and shared, which was provided to them and is in accord with the privacy and data-protection policy of the Weizmann Institute of Science (https://weizmann.ac.il/pages/privacy-policy).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesModels and tables of de-identified, aggregated data are available at https://github.com/hrossman/Covid19-Survey. https://github.com/hrossman/Covid19-Survey